Form 8-K/A date of report 06-06-24 true 0001549084 0001549084 2024-06-06 2024-06-06
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K/A
 
(Amendment No. 1)
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
June 6, 2024
Date of Report (date of earliest event reported)
 
Ekso Bionics Holdings, Inc.
(Exact name of registrant as specified in its charter)
 
Nevada
001-37854
99-0367049
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
101 Glacier Point, Suite A        San Rafael        California
94901
(Address of Principal Executive Offices)
(Zip Code)
 
(510) 984-1761
Registrant's telephone number, including area code
 
Not Applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
EKSO
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
☐
 
 
 
 
Explanatory Note
 
On June 10, 2024, Ekso Bionics Holdings, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) with the U.S. Securities and Exchange Commission to report the voting results on the matters submitted to a vote of the Company’s stockholders at the Company’s 2024 Annual Meeting of Stockholders held on June 6, 2024 (the “Annual Meeting”). This Amendment No. 1 to the Initial 8-K is being filed in order to disclose the Company’s decision on how frequently it will include a stockholder proposal in its proxy materials regarding the compensation of the Company’s named executive officers in light of the stockholder vote on frequency of future advisory vote on executive compensation at the Annual Meeting. No other changes are being made to the Initial 8-K.
 
Item 5.07.         Submission of Matters to a Vote of Security Holders.
 
On July 25, 2024, the board of directors the Company (the “Board”) determined that the Company will hold a stockholder future advisory vote on compensation of the Company’s named executive officers annually. This frequency is consistent with the Board’s recommendation in the proxy statement relating to Annual Meeting and with the voting results at the Annual Meeting.
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  EKSO BIONICS HOLDINGS, INC.
  By: /s/ Jerome Wong
  Name: Jerome Wong
  Title:  Chief Financial Officer
     
  Dated: July 26, 2024
 
 
v3.24.2
Document And Entity Information
Jun. 06, 2024
Document Information [Line Items]  
Entity, Registrant Name Ekso Bionics Holdings, Inc.
Document, Type 8-K/A
Document, Period End Date Jun. 06, 2024
Entity, Incorporation, State or Country Code NV
Entity, File Number 001-37854
Entity, Tax Identification Number 99-0367049
Entity, Address, Address Line One 101 Glacier Point, Suite A
Entity, Address, City or Town San Rafael
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94901
City Area Code 510
Local Phone Number 984-1761
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol EKSO
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Description Form 8-K/A date of report 06-06-24
Amendment Flag true
Entity, Central Index Key 0001549084
Ekso Bionics (NASDAQ:EKSO)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Ekso Bionics.
Ekso Bionics (NASDAQ:EKSO)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Ekso Bionics.